Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution

• Published in: Biomedicines 2023-08, Vol.11 (8), p.2269
• Main Authors: Koh, Hyun-Hee, Park, Eunhyang, Kim, Hyun-Soo
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Apoptosis; Cancer; Cell death; Chromosome 10; Chromosome deletion; Clinical trials; Comparative analysis; Consortia; Development and progression; Disease management; Gene mutations; Genetic aspects; Genomes; Genomics; Hybridization; immunohistochemistry; Instrument industry; K-Ras protein; Labeling; Medical prognosis; mesonephric-like adenocarcinoma; Metastases; Metastasis; Mismatch repair; Morphology; Mutation; p53 Protein; programmed cell death-ligand 1; Proteins; PTEN protein; Sarcoma; Software; targeted sequencing; Tensin; Tumor proteins; Tumors; Uterus
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11082269

Data on genetic and immunophenotypical characteristics of uterine mesonephric-like adenocarcinoma (MLA) remain limited. Therefore, we aimed to investigate the clinicopathological, immunohistochemical, and molecular features of uterine MLA. We performed targeted sequencing, array comparative genomic hybridization, and immunostaining in 17, 13, and 17 uterine MLA cases, respectively. Nine patients developed lung metastases. Eleven patients experienced disease recurrences. The most frequently mutated gene was Kirsten rat sarcoma viral oncogene homolog (KRAS; 13/17). Both the primary and matched metastatic tumors harbored identical KRAS (3/4) and phosphatase and tensin homolog deleted on chromosome 10 (1/4) mutations, and did not harbor any additional mutations. A total of 2 of the 17 cases harbored tumor protein 53 (TP53) frameshift insertion and deletion, respectively. Chromosomal gains were detected in 1q (13/13), 10 (13/13), 20 (10/13), 2 (9/13), and 12 (6/13). Programmed cell death-ligand 1 overexpression or mismatch repair deficiency was not observed in any of the cases. Initial serosal extension and lung metastasis independently predicted recurrence-free survival with hazard ratios of 6.30 and 7.31, respectively. Our observations consolidated the clinicopathological and molecular characteristics of uterine MLA. Both clinicians and pathologists should consider these features to make an accurate diagnosis of uterine MLA and to ensure appropriate therapeutic management of this rare entity.